DK167139B1 - Fremgangsmaade til fremstilling af en stabil doseringsform af en pge2-forbindelse (prostaglandin e2) - Google Patents
Fremgangsmaade til fremstilling af en stabil doseringsform af en pge2-forbindelse (prostaglandin e2) Download PDFInfo
- Publication number
- DK167139B1 DK167139B1 DK127883A DK127883A DK167139B1 DK 167139 B1 DK167139 B1 DK 167139B1 DK 127883 A DK127883 A DK 127883A DK 127883 A DK127883 A DK 127883A DK 167139 B1 DK167139 B1 DK 167139B1
- Authority
- DK
- Denmark
- Prior art keywords
- pge2
- gel
- gels
- prostaglandin
- pge
- Prior art date
Links
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title claims description 23
- -1 PGE2 COMPOUND Chemical class 0.000 title claims description 12
- 229960002986 dinoprostone Drugs 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 11
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title claims description 9
- 239000002552 dosage form Substances 0.000 title claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 29
- 239000008119 colloidal silica Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000000499 gel Substances 0.000 description 43
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 30
- 239000001087 glyceryl triacetate Substances 0.000 description 15
- 235000013773 glyceryl triacetate Nutrition 0.000 description 15
- 229960002622 triacetin Drugs 0.000 description 15
- 239000000243 solution Substances 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 230000000087 stabilizing effect Effects 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001940 cyclopentanes Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002997 prostaglandinlike Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8208322 | 1982-03-22 | ||
| GB8208322 | 1982-03-22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK127883D0 DK127883D0 (da) | 1983-03-21 |
| DK127883A DK127883A (da) | 1983-09-23 |
| DK167139B1 true DK167139B1 (da) | 1993-09-06 |
Family
ID=10529176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK127883A DK167139B1 (da) | 1982-03-22 | 1983-03-21 | Fremgangsmaade til fremstilling af en stabil doseringsform af en pge2-forbindelse (prostaglandin e2) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4680312A (enExample) |
| EP (1) | EP0089768B1 (enExample) |
| JP (1) | JPS58167509A (enExample) |
| DE (1) | DE3381898D1 (enExample) |
| DK (1) | DK167139B1 (enExample) |
| FI (1) | FI81962C (enExample) |
| HK (1) | HK91993A (enExample) |
| NO (1) | NO163042C (enExample) |
| ZA (1) | ZA831186B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61277622A (ja) * | 1985-05-31 | 1986-12-08 | Teijin Ltd | 活性型ビタミンｄ３類製剤用組成物 |
| WO1994006452A1 (en) * | 1992-09-21 | 1994-03-31 | The Upjohn Company | Sustained-release protein formulations |
| US5939090A (en) * | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
| JP2001509480A (ja) | 1997-07-09 | 2001-07-24 | アンドロソリューションズ，インク． | 男性勃起機能不全を治療するための改良された方法及び組成物 |
| US6103765A (en) | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
| US6593369B2 (en) | 1997-10-20 | 2003-07-15 | Vivus, Inc. | Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
| US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| AU740758B2 (en) | 1997-10-28 | 2001-11-15 | Vivus, Inc. | Treatment of female sexual dysfunction |
| US20050070516A1 (en) * | 1997-10-28 | 2005-03-31 | Vivus Inc. | As-needed administration of an androgenic agent to enhance female desire and responsiveness |
| US20020009478A1 (en) * | 1998-08-24 | 2002-01-24 | Douglas Joseph Dobrozsi | Oral liquid mucoadhesive compositions |
| US20070191320A1 (en) * | 1998-12-10 | 2007-08-16 | Nexmed Holdings, Inc. | Methods of treatment for female sexual arousal disorder |
| US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| RU2223101C2 (ru) * | 2001-10-04 | 2004-02-10 | Санкт-Петербургская Государственная Химико-Фармацевтическая Академия | Набор для стимуляции родовой деятельности |
| WO2012133554A1 (ja) * | 2011-03-31 | 2012-10-04 | 富士フイルム株式会社 | プロスタグランジン含有脂肪乳剤 |
| PL2958550T3 (pl) | 2013-02-25 | 2023-01-16 | Sun Pharmaceutical Industries Limited | Doustna postać użytkowa i zawiesina leku onkologicznego |
| AT515356B1 (de) * | 2014-01-30 | 2015-11-15 | Gebro Holding Gmbh | Stabile alkoholische Lösung von Alprostadil |
| CN107496348A (zh) * | 2017-08-28 | 2017-12-22 | 天津昂赛细胞基因工程有限公司 | 一种用于组织损伤修复的水凝胶及制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS503362B1 (enExample) * | 1970-06-10 | 1975-02-04 | ||
| US3829579A (en) * | 1971-11-01 | 1974-08-13 | Upjohn Co | Stable solutions of pge-type compounds |
| US3749800A (en) * | 1971-11-01 | 1973-07-31 | Upjohn Co | Stable composition for dispensing pge2 |
| US3826823A (en) * | 1972-09-25 | 1974-07-30 | Syntex Inc | Stabilized prostaglandin preparations |
| US3927197A (en) * | 1974-04-19 | 1975-12-16 | Pfizer | Tertiary alcohol stabilized E-series prostaglandins |
| JPS51136818A (en) * | 1975-05-20 | 1976-11-26 | Yamanouchi Pharmaceut Co Ltd | Method for preparing stable prostaglandine pharma ceuticals |
| US3966962A (en) * | 1975-03-27 | 1976-06-29 | The Upjohn Company | Triacetin solutions of PGE-type compounds |
| JPS6043335B2 (ja) * | 1976-05-21 | 1985-09-27 | 山之内製薬株式会社 | 安定なプロスタグランジンｅ類含有組成物 |
| SE431821B (sv) * | 1979-01-29 | 1984-03-05 | Perstorp Ab | Lagringsstabilt, prostaglandininnehallande medicinskt preparat |
| US4211793A (en) * | 1979-03-19 | 1980-07-08 | American Cyanamid Company | Triethyl citrate solutions of PGE-type compounds |
| NZ193221A (en) * | 1979-03-21 | 1984-08-24 | M P Embrey | Controlled release composition |
| JPS6033429B2 (ja) * | 1980-04-28 | 1985-08-02 | 小野薬品工業株式会社 | プロスタグランジン類似化合物 |
| JPS6033430B2 (ja) * | 1980-05-12 | 1985-08-02 | 小野薬品工業株式会社 | プロスタグランジン類似化合物 |
-
1983
- 1983-02-22 ZA ZA831186A patent/ZA831186B/xx unknown
- 1983-03-07 EP EP83301200A patent/EP0089768B1/en not_active Expired - Lifetime
- 1983-03-07 DE DE8383301200T patent/DE3381898D1/de not_active Expired - Lifetime
- 1983-03-15 JP JP58041640A patent/JPS58167509A/ja active Granted
- 1983-03-17 FI FI830890A patent/FI81962C/fi not_active IP Right Cessation
- 1983-03-21 DK DK127883A patent/DK167139B1/da not_active IP Right Cessation
- 1983-03-21 NO NO830988A patent/NO163042C/no not_active IP Right Cessation
-
1984
- 1984-11-21 US US06/674,357 patent/US4680312A/en not_active Expired - Lifetime
-
1993
- 1993-09-02 HK HK919/93A patent/HK91993A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI830890A0 (fi) | 1983-03-17 |
| HK91993A (en) | 1993-09-10 |
| DK127883A (da) | 1983-09-23 |
| NO163042C (no) | 1990-04-18 |
| EP0089768A1 (en) | 1983-09-28 |
| JPH0322850B2 (enExample) | 1991-03-27 |
| FI830890L (fi) | 1983-09-23 |
| DE3381898D1 (de) | 1990-10-31 |
| ZA831186B (en) | 1983-11-30 |
| US4680312A (en) | 1987-07-14 |
| DK127883D0 (da) | 1983-03-21 |
| FI81962C (fi) | 1991-01-10 |
| NO163042B (no) | 1989-12-18 |
| JPS58167509A (ja) | 1983-10-03 |
| EP0089768B1 (en) | 1990-09-26 |
| FI81962B (fi) | 1990-09-28 |
| NO830988L (no) | 1983-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK167139B1 (da) | Fremgangsmaade til fremstilling af en stabil doseringsform af en pge2-forbindelse (prostaglandin e2) | |
| RU2085191C1 (ru) | Жидкая антибактериальная композиция | |
| KR100634571B1 (ko) | 연질 젤라틴 제제용 약학 조성물의 제조 방법 | |
| NO169155B (no) | Fremgangsmaate for fremstilling av ibuprofenholdige kapsler av myk gelatin | |
| JPS62190119A (ja) | 高粘度ヒドロゲル又は懸濁液を得るための製剤 | |
| JP7409772B2 (ja) | ダントロレンを含む水性組成物 | |
| KR20130081653A (ko) | 열감응성 겔 마취제 조성물 | |
| JPS61100528A (ja) | ニフエジピン含有薬剤組成物とその製造方法 | |
| JPH02286615A (ja) | 経口投与用イブプロフェン組成物 | |
| JPS5910598A (ja) | 安定なインタ−フエロンβ組成物およびインタ−フエロンβの安定化方法 | |
| PH26546A (en) | Topical preparation containing ofloxacin | |
| EP2219640A2 (en) | Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same | |
| CA1249223A (en) | Solid drug formulations and stable suspensions | |
| CA2865555C (en) | Controlled release compositions and their methods of use | |
| WO2012037834A1 (zh) | 一种5α-雄甾（烷）-3β，5，6β-三醇注射剂及其制备方法 | |
| JP6672512B2 (ja) | 一酸化窒素放出プロスタミドを含有する眼科用組成物 | |
| CN113520995A (zh) | 一种离子敏感型眼用原位凝胶、其制备方法及应用 | |
| CN113842358B (zh) | 一种兽用子宫注入剂及其制备方法和应用 | |
| CA1180276A (en) | Gelled pge.sub.2/triacetin solutions | |
| JP4475405B2 (ja) | 医薬組成物 | |
| JP2001519395A (ja) | カルバマゼピンまたはその誘導体を含む非経口製剤 | |
| JP3459349B2 (ja) | ラクツロースをベースとする無水組成物 | |
| KR0137647B1 (ko) | 이보파민의 수용성 산 부가 염을 포함하는 안과용 약학 조성물 | |
| ITTO20070479A1 (it) | Composizione veterinaria iniettabile ad attivita' anti-prolattinica | |
| ITMI972365A1 (it) | Composizione a base di tiamfenicolo e diclofenac |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed | ||
| B1 | Patent granted (law 1993) | ||
| PUP | Patent expired |